Skip to content

PAR-25-153 NCI Assay Screening R01 Eligibility Guide

Updated 3 official sources

Quick Answer: PAR-25-153 eligibility in 2026 turns on 6 checks: cancer relevance, assay or screening stage, preliminary feasibility, chemistry or cheminformatics input, clinical trial not allowed status, and a validated output path.

Full answer and how we checked it

PAR-25-153 eligibility in 2026 turns on 6 checks: cancer relevance, assay or screening stage, preliminary feasibility, chemistry or cheminformatics input, clinical trial not allowed status, and a validated output path.

Who this is for: Cancer biology labs, assay-development teams, screening centers, chemical biology groups, immunology teams, medicinal chemistry collaborators, and sponsored-research offices deciding whether a discovery-stage NCI R01 fits.

Data note: This guide uses NIH PAR-25-153 (opens in a new tab), NIH clinical trials policy (opens in a new tab), Grants.gov listing 357014 (opens in a new tab), and Grantsights award-data signals checked on June 2, 2026.

In this guide

PAR-25-153 is not a general cancer R01. According to NIH PAR-25-153 (opens in a new tab), the route supports discovery research for identifying small molecules that can clarify cancer biology as chemical probes or act as activators or inhibitors of cancer targets.

Some assay projects pair strong biology with an underbuilt screening path. For this route, the application must prove that the assay, screen, and hit-validation logic can survive R01 review.

Use this guide with the live NCI Assay Screening R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Cancer Nanotechnology R01 guide, and the Grantsights grant database.

Source Check

Checked June 2026.

6 official-source checks should happen before a team treats PAR-25-153 as the right R01. NIH listed PAR-25-153 as an NCI R01, clinical trial not allowed, with standard due dates through its September 8, 2026 expiration; the notice has expired, so check PAR-25-153's NIH Guide listing (opens in a new tab) for a reissue. NIH also states that supported discovery stages include primary assay development with pilot screening, primary screen work to identify initial hits, and hit validation with orthogonal assays, cheminformatics, and initial medicinal chemistry inspection.

The route is narrow by stage, not only by topic. A cancer biology project can be strong and still belong in a parent R01 if the assay or screen is not central. A chemistry project can be strong and still miss this route if detailed SAR, ADME, clinical, or late product work dominates.

Source checkWhat to verify before writing
Trial statusNo NIH-defined clinical trial is proposed
Cancer relevanceTarget, pathway, phenotype, or immune process is tied to cancer
Stage fitAssay development, primary screen, or hit validation is the core work
FeasibilityPreliminary assay quality supports the requested stage
Validation pathOrthogonal assays, counterscreens, and compound-quality review are named
Better routeParent R01, R21, SBIR/STTR, or later translation route is compared

The strongest first memo line is simple: this project is a cancer-relevant, non-trial R01 because the assay, screen, or hit-validation stage is ready enough to review.

Get research funding calls by email

About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.

No spam. Unsubscribe anytime.

6 PAR-25-153 Eligibility Stop Checks

6 stop checks decide whether this R01 fits. The project should be cancer-relevant, discovery-stage, non-trial, and built around assay or screening work that can identify useful small-molecule tools or leads.

Stop checkStrong R01 signalRed flag
Cancer relevanceTarget or pathway is tied to cancer biology or controlCancer connection is weak
Stage fitAssay development, screening, or hit validation is centralLate SAR, ADME, or clinical work dominates
FeasibilityPreliminary assay quality or screen plan is crediblePrimary assay is speculative
Chemistry roleMedicinal chemistry or cheminformatics input is presentHit quality will not be assessed
Trial statusNo NIH-defined clinical trialHuman intervention assignment is planned
OutputProbe, hit set, or validated screen can inform next workOutput is vague

Don't use this route when the main project is target biology without a screen, or drug development after a hit is already mature.

5 Funding, Timing, and Mechanism Rules

5 public rules should appear in the routing memo. According to NIH, PAR-25-153 is an R01 research project grant and clinical trials are not allowed. PAR-25-153 used NIH standard due dates; the last cycle was June 5, 2026 for new applications and July 5, 2026 for renewals and resubmissions, and the notice expired September 8, 2026; check PAR-25-153's NIH Guide listing (opens in a new tab) for a reissue.

RuleSource-backed read
Funding numberPAR-25-153
MechanismR01 research project grant
Clinical trial statusNot allowed
Core stagesAssay development, screen implementation, hit validation
Last due datesJune 5, 2026 (new) and July 5, 2026 (renewal/resubmission) have passed, and the notice expired September 8, 2026; check NIH for a reissue before planning a submission

USASpending.gov data shows about $1.14B in FY2024 obligations across 3,308 awards active that year for the connected assistance-listing family in Grantsights. That scale makes the route worth evaluating, but it also means weak fit will not stand out.

5 Route Choices Before Drafting

5 route choices matter because not every cancer chemical biology project belongs here.

RouteBetter first read when...Why
PAR-25-153 R01Assay, screen, or hit validation is centralProgram fit is strong
Parent R01Cancer biology is central but screen work is notBroader route may fit
R21 or pilotAssay feasibility is too earlyR01 may be premature
SBIR/STTRCompany-led development is centralSmall-business path may fit
Later translation routeLead optimization or product development dominatesThis route may be too early

The best first move is to name the project stage. If the application tries to do assay development, full screening, validation, SAR, and in vivo development all at once, it is probably overbuilt.

What NIH Doesn't Tell You

4 hidden readiness questions decide whether PAR-25-153 is worth pursuing.

First, NIH does not make every assay an R01 project. The assay should answer a cancer-relevant problem and support chemical probe or drug discovery logic.

Second, NIH does not let hit validation be an afterthought. Counterscreens, orthogonal assays, selectivity checks, and compound-quality review should be visible.

Third, NIH does not fund detailed SAR or ADME work through this route. Those may be logical next steps, but they are outside the core program fit.

Fourth, NIH does not make clinical trials possible here. The work should remain discovery and preclinical.

According to NIH, PAR-25-153 is Clinical Trial Not Allowed. According to Grants.gov, listing 357014 is the federal listing tied to this route. If the team cannot show controls, signal window, reproducibility, orthogonal validation, and a chemistry triage plan, skip the R01 for now and choose a better route or pilot path.

7 Evidence Assets That Make This R01 Stronger

7 evidence assets make the application easier to defend.

First, define the target or phenotypic system. The cancer relevance should be specific enough for reviewers to judge.

Second, state the stage. NIH names assay development and pilot screening, screen implementation, and hit validation. The application should say which stage it is built around.

Third, show assay quality. Signal window, reproducibility, controls, interference risk, throughput, and validation data matter.

Fourth, include orthogonal validation. A primary screen without a second way to test hits is fragile.

Fifth, include chemistry review. One university in Texas screening small molecules against a fusion oncoprotein model could strengthen its case by adding chemotype triage, PAINS checks, and powder retesting before deeper follow-up.

Sixth, set realistic output. The award should produce an assay, a screen, a validated hit set, or a probe path, not a finished drug.

Seventh, compare next routes. If the project succeeds, the next step may be R01 continuation, SBIR/STTR, NCI translational support, or a chemistry-focused route.

7 Source-Backed Search Questions

7 search questions should be answered clearly. The first is whether PAR-25-153 is cancer-specific. Yes, NCI frames the route around cancer-relevant targets, probes, drugs, and immunomodulators.

The second is whether clinical trials are allowed. They aren't. A human intervention study needs another route.

The third is which project stage fits. NIH names assay development with pilot screening, primary screen implementation, and hit validation.

The fourth is whether the project can cover more than one stage. It can, but NIH expects feasibility and support for the stages proposed.

The fifth is whether hit validation needs chemistry input. The honest read is yes. A screen without chemistry triage can look underbuilt.

The sixth is whether extensive SAR or ADME work fits. NIH lists those as outside this route, so a late development project should look elsewhere.

The seventh is whether a phenotypic screen can fit. It can, but the mechanism and target-deconvolution plan should be credible.

21-Day R01 Routing Plan

21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm PAR-25-153 status, deadline, trial status, cancer relevance, and stage fit.

Days 4 through 7 should build the assay-readiness table: target, readout, controls, signal, throughput, pilot data, and failure thresholds.

Days 8 through 12 should write the screen plan: library, format, counterscreens, false-positive control, and validation assays.

Days 13 through 16 should add chemistry review and hit-prioritization logic.

Days 17 through 21 should compare routes and prepare program-staff questions.

6 Reviewer-Risk Signals to Fix

6 risk signals should be fixed before submission. First, the cancer relevance should not be generic.

Second, the primary assay should not be untested.

Third, the project should not skip orthogonal validation.

Fourth, chemistry input should not be missing if hit triage is central.

Fifth, the application should not promise late-stage development work that the NOFO does not support.

Sixth, the trial status should be clear.

4 Signals To Check Before You Draft

4 signals help you decide whether to draft. Signal 1 is cancer fit: the target, pathway, or phenotype should be specific enough for NCI review.

Signal 2 is stage fit: assay development, screen implementation, and hit validation require different evidence.

Signal 3 is validation fit: orthogonal assays, counterscreens, selectivity checks, and compound-quality review should be visible.

Signal 4 is route fit: compare parent R01, R21, SBIR/STTR, cancer nanotechnology, and academic-industrial translation before drafting.

5 Applicant Types and Best Next Move

5 applicant types commonly ask about PAR-25-153.

Applicant typeBest next moveWhy
Assay-development labBuild assay-readiness tableRoute may fit
Screening centerDefine validation and chemistry planHit quality matters
Cancer biology PIConfirm screen is centralParent R01 may fit better
Company-led projectCompare SBIR/STTRBusiness route may fit
Sponsored-project officeCheck trial status and deadlineTechnical fit can block

The best answer is: use PAR-25-153 when the project is cancer-relevant, non-trial, and centered on assay development, screening, or hit validation that can support chemical probe or drug discovery.

If the project can't show assay quality, validation logic, and cancer relevance, don't chase this R01 yet.

8 Applicant Memo Lines to Include

8 memo lines help separate a strong PAR-25-153 project from a broad cancer biology proposal. According to Grantsights data, the connected NCI assistance-listing family recorded about $1.14B in FY2024 obligations, so a weak stage-fit argument is not enough. Line 1 should name the cancer target, pathway, immune process, or phenotype and explain why it matters.

Line 2 should state the stage: primary assay development, initial pilot screen, primary screen implementation, hit validation, or a justified combination.

Line 3 should describe the assay readout, control set, expected signal window, and artifact risks. If the assay is not ready, the memo should say what data will make it ready.

Line 4 should explain how hits will be validated. Orthogonal assays, target-minus controls, cytotoxicity checks, and selectivity assays should not be left for later.

Line 5 should name the chemistry or cheminformatics role. The application should show how the team will avoid poor chemotypes and false-positive compounds.

Line 6 should define the cancer relevance of the output. The final product does not need to be a drug, but it should help chemical probe or drug discovery logic.

Line 7 should state why clinical trials, SAR, and ADME work are outside the project.

Line 8 should define the next route if the screen works. The next step could be a parent R01, a later NCI route, SBIR/STTR, or a chemistry-focused path.

6 Common Route Mistakes

6 mistakes show up often in assay and screening applications. First, teams sometimes pick this route for broad target biology even when the screen is not central. That weakens fit.

Second, teams overpromise the stage. A project can start with assay development, but it should not imply a full discovery pipeline unless preliminary data justify that scope.

Third, teams underbuild hit validation. Reviewers know primary screens can produce large numbers of false positives. The application should show the validation funnel.

Fourth, teams forget medicinal chemistry review. Even early discovery projects need a credible way to judge compound quality.

Fifth, teams blur the line between probe discovery and product development. PAR-25-153 can set up later work, but it isn't a late-stage drug-development route.

Sixth, teams leave route comparison until after writing. It is better to compare parent R01, R21, SBIR/STTR, and NCI translation routes before the first draft.

9 Review-Ready Proof Points

USASpending.gov data shows about $1.14B in FY2024 obligations for the connected NCI assistance-listing family. First, the project should name the target or phenotype. Second, the assay should have controls. Third, the detection method should be matched to the biology. Fourth, the pilot screen should have a realistic compound set. Fifth, the validation plan should include orthogonal assays. Sixth, chemistry review should flag poor compounds early. Seventh, the project should avoid clinical work. Eighth, the output should be a probe, hit set, or validated screen. Ninth, the next route should be clear.

According to NIH, PAR-25-153 covers 3 main discovery stages: assay development with pilot screening, primary screen implementation, and hit validation. That 3-stage frame is the best way to keep the application focused.

The official rule question is simple: what does NIH allow? The judgment question is harder: is the assay mature enough, are the hits likely to be real, and does the team have the chemistry skill to interpret them? A searcher who gets both answers from Grantsights has less reason to bounce back to Google.

A team doing detailed SAR, ADME, or clinical work should leave with a different route in mind. A team with a weak primary assay should leave with a pilot plan. A team with a strong assay but no hit-validation funnel should know what to fix before drafting.

Sources

3 sources anchor this guide: the NIH NCI R01 NOFO, the federal listing, and the Grantsights public database record.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-153 fund?

NIH says the R01 supports NCI discovery research for assay development, screening, and hit validation for chemical probes, drugs, or immunomodulators relevant to cancer.

Are clinical trials allowed?

No. PAR-25-153 is clinical trial not allowed.

Which project stages fit?

NIH names primary assay development and pilot screening, screen implementation, and hit validation as supported stages.

Who should skip this route?

Skip it if the target is not cancer-relevant, the project is detailed SAR or ADME work, or the proposal needs a clinical trial.

What is the strongest first check?

Confirm the assay or screen stage, cancer relevance, preliminary feasibility, hit-validation path, and chemistry expertise.

Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.